(Total Views: 480)
Posted On: 09/09/2021 8:45:57 AM
Post# of 148903
The FDA's statement to HGEN says it all:
"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19."
What's unclear? HGEN's treatment has known risks that the FDA doesn't like. Leronlimab, does not. Not rocket science.
"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19."
What's unclear? HGEN's treatment has known risks that the FDA doesn't like. Leronlimab, does not. Not rocket science.
(10)
(0)Scroll down for more posts ▼
